
NUTX
Nutex Health Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
84.000
Open
84.000
VWAP
84.00
Vol
1.70K
Mkt Cap
466.63M
Low
84.000
Amount
142.72K
EV/EBITDA(TTM)
3.36
Total Shares
49.72M
EV
768.58M
EV/OCF(TTM)
10.81
P/S(TTM)
0.61
Nutex Health Inc. is a healthcare management and operations company. The Company operates in three segments: the Hospital division, the Population Health Management (PHM) division, and the Real Estate division. The Hospital division owns, develops and operates healthcare models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. In addition, it has financial and operating relationships with multiple professional entities and real estate entities. The Population Health Management division owns and operates provider networks, such as Independent Physician Associations (IPAs). Through its Management Services Organization (MSO), it provides management, administrative and other support services to its affiliated hospitals and physician groups. The Real Estate division comprises the Real Estate Entities, which owns the land and hospital buildings which are leased to its hospital entities.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
181.86M
-29.41%
--
--
173.22M
+119.83%
--
--
176.47M
+131.95%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Nutex Health Inc. (NUTX) for FY2025, with the revenue forecasts being adjusted by 37.1% over the past three months. During the same period, the stock price has changed by -28.81%.
Revenue Estimates for FY2025
Revise Upward

+37.1%
In Past 3 Month
Stock Price
Go Down

-28.81%
In Past 3 Month
2 Analyst Rating

212.50% Upside
Wall Street analysts forecast NUTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUTX is 262.50 USD with a low forecast of 225.00 USD and a high forecast of 300.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy

212.50% Upside
Current: 84.000

Low
225.00
Averages
262.50
High
300.00

212.50% Upside
Current: 84.000

Low
225.00
Averages
262.50
High
300.00
Maxim
Maxim
Buy
maintain
$100 -> $225
2025-05-20
Reason
Maxim
Maxim
Price Target
$100 -> $225
2025-05-20
maintain
Buy
Reason
Maxim raised the firm's price target on Nutex Health to $225 from $100 and keeps a Buy rating on the shares. The company's Q1 results were sharply above consensus as it recognized $105M in revenue from Independent Dispute Resolution arbitration, the analyst tells investors in a research note. Nutex remains on-track to open three de novo mirco-hospitals during 2025, all of which should be "second half of 2025 events", Maxim adds.
Benchmark
Buy
upgrade
$150 -> $300
2025-05-15
Reason
Benchmark
Price Target
$150 -> $300
2025-05-15
upgrade
Buy
Reason
Benchmark raised the firm's price target on Nutex Health to $300 from $150 and keeps a Buy rating on the shares based on "another big beat" in Q1 and positive updates to the firm's model. Based on greater visibility into the sustainability of rate arbitration success realization, the firm is "significantly lifting" its FY25 and FY26 outlooks for revenue, adjusted EBITDA and GAAP EPS, the analyst tells investors, adding that Nutex remains a "Benchmark Best Idea."
Maxim Group
Anthony Vendetti
Strong Buy
Maintains
$75 → $100
2025-04-08
Reason
Maxim Group
Anthony Vendetti
Price Target
$75 → $100
2025-04-08
Maintains
Strong Buy
Reason
Maxim raised the firm's price target on Nutex Health to $100 from $75 and keeps a Buy rating on the shares. The company delivered significantly better-than-expected Q4 results, driven largely by the company's success in achieving improved reimbursement by advancing claims through the No Surprises Act's IDR - independent dispute resolution - process, the analyst tells investors in a research note. Beyond IDR activity, Nutex continues to advance its core growth strategy, with its hospitals expanding service lines to treat higher-acuity patients and to drive increased inpatient and observation visit volumes, the firm adds.
Maxim Group
Anthony Vendetti
Strong Buy
Maintains
$50 → $75
2025-02-13
Reason
Maxim Group
Anthony Vendetti
Price Target
$50 → $75
2025-02-13
Maintains
Strong Buy
Reason
Maxim Group
Anthony Vendetti
Strong Buy
Maintains
$45 → $50
2024-11-12
Reason
Maxim Group
Anthony Vendetti
Price Target
$45 → $50
2024-11-12
Maintains
Strong Buy
Reason
Maxim raised the firm's price target on Nutex Health to $50 from $45 and keeps a Buy rating on the shares. The company's Q3 results topped estimates, with positive trends in metrics fueling its growth, the analyst tells investors in a research note. Maxim adds that the firm expects Nutex to generate $8.9M in operating cash per quarter through 2025 and believes that the company has sufficient capital to maintain current operations, even though it may raise capital to accelerate new hospital openings.
Benchmark
Bill Sutherland
Strong Buy
Maintains
$45 → $60
2024-11-12
Reason
Benchmark
Bill Sutherland
Price Target
$45 → $60
2024-11-12
Maintains
Strong Buy
Reason
Benchmark analyst Bill Sutherland raised the firm's price target on Nutex Health to $60 from $45 and keeps a Buy rating on the shares after what the firm calls "another big beat from top to bottom," with revenue and AEBITDA growth of 26% and 974%, respectively. Initiatives to increase patient volumes with a focus on higher value services point to continued growth and margin expansion, the analyst tells investors.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Nutex Health Inc (NUTX.O) is 12.78, compared to its 5-year average forward P/E of -28.26. For a more detailed relative valuation and DCF analysis to assess Nutex Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-28.26
Current PE
12.78
Overvalued PE
73.12
Undervalued PE
-129.63
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
67.69
Current EV/EBITDA
3.66
Overvalued EV/EBITDA
181.34
Undervalued EV/EBITDA
-45.96
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
3.37
Current PS
0.66
Overvalued PS
10.97
Undervalued PS
-4.23
Financials
Annual
Quarterly
FY2025Q1
YoY :
+213.98%
211.79M
Total Revenue
FY2025Q1
YoY :
+4881.30%
72.21M
Operating Profit
FY2025Q1
YoY :
-8251.90%
44.22M
Net Income after Tax
FY2025Q1
YoY :
-3300.00%
2.56
EPS - Diluted
FY2025Q1
YoY :
+2096.34%
50.90M
Free Cash Flow
FY2025Q1
YoY :
+271.05%
55.88
Gross Profit Margin - %
FY2025Q1
YoY :
-1212.00%
11.12
FCF Margin - %
FY2025Q1
YoY :
-2710.00%
20.88
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
81.8K
USD
Months
6-9
0
0.0
USD
Months
0-12
3
62.2K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
81.8K
USD
Months
6-9
0
0.0
USD
Months
0-12
3
62.2K
USD
Months
NUTX News & Events
Events Timeline
2025-07-23 (ET)
2025-07-23
20:39:15
Nutex Health 'strongly disagrees' with allegations in short report

2025-07-22 (ET)
2025-07-22
13:38:46
Nutex Health down 2% after Blue Orca publishes short report

2025-07-22
13:38:39
Blue Orca Capital short Nutex Health, says stock 'un-investable'


Sign Up For More Events
Sign Up For More Events
News
1.0
07-29NewsfilterNUTEX HEALTH TO RING NASDAQ BELL AND MEET WITH INVESTORS IN NYC ON AUGUST 26
7.0
07-28PRnewswireNutex Health (NUTX) Shares Fall Amid Critical Blue Orca Report -- Hagens Berman
7.0
07-28GlobenewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nutex Health Inc. - NUTX
Sign Up For More News
People Also Watch

OBIO
Orchestra Biomed Holdings Inc
3.120
USD
0.00%

GAUZ
Gauzy Ltd
6.900
USD
0.00%

MBCN
Middlefield Banc Corp
28.350
USD
0.00%

SWKH
SWK Holdings Corp
15.000
USD
0.00%

HURA
TuHURA Biosciences Inc
2.580
USD
0.00%

HMST
HomeStreet Inc
12.740
USD
0.00%

FTEL
Fitell Corp
0.565
USD
0.00%

CGEN
Compugen Ltd
1.440
USD
0.00%

KNOP
Knot Offshore Partners LP
6.850
USD
-1.30%

ESSA
ESSA Bancorp Inc
20.690
USD
+2.47%
FAQ

What is Nutex Health Inc (NUTX) stock price today?
The current price of NUTX is 84 USD — it has increased 0 % in the last trading day.

What is Nutex Health Inc (NUTX)'s business?

What is the price predicton of NUTX Stock?

What is Nutex Health Inc (NUTX)'s revenue for the last quarter?

What is Nutex Health Inc (NUTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Nutex Health Inc (NUTX)'s fundamentals?

How many employees does Nutex Health Inc (NUTX). have?
